7.30
price up icon0.41%   0.03
after-market アフターアワーズ: 6.85 -0.45 -6.16%
loading
前日終値:
$7.27
開ける:
$7
24時間の取引高:
207.50K
Relative Volume:
0.56
時価総額:
$166.70M
収益:
$155.00K
当期純損益:
$-30.01M
株価収益率:
-4.3713
EPS:
-1.67
ネットキャッシュフロー:
$-11.98M
1週間 パフォーマンス:
-6.53%
1か月 パフォーマンス:
-8.98%
6か月 パフォーマンス:
+39.31%
1年 パフォーマンス:
-29.40%
1日の値動き範囲:
Value
$6.545
$7.4459
1週間の範囲:
Value
$6.545
$8.16
52週間の値動き範囲:
Value
$4.32
$12.72

Inmune Bio Inc Stock (INMB) Company Profile

Name
名前
Inmune Bio Inc
Name
セクター
Healthcare (1188)
Name
電話
(858) 964-3720
Name
住所
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Name
職員
0
Name
Twitter
@INmuneBio
Name
次回の収益日
2025-03-25
Name
最新のSEC提出書
Name
INMB's Discussions on Twitter

INMB を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
INMB
Inmune Bio Inc
7.30 166.70M 155.00K -30.01M -11.98M -1.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.56 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.78 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
550.00 33.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.95 30.15B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
220.54 25.69B 3.81B -644.79M -669.77M -6.24

Inmune Bio Inc Stock (INMB) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-01-28 開始されました Rodman & Renshaw Buy
2024-10-21 開始されました Alliance Global Partners Buy
2024-09-27 開始されました Raymond James Outperform
2024-08-22 開始されました Scotiabank Sector Outperform
2023-06-01 開始されました Robert W. Baird Outperform
2022-05-24 ダウングレード B. Riley Securities Buy → Neutral
2021-07-07 繰り返されました Maxim Group Buy
2021-04-21 開始されました B. Riley Securities Buy
2021-01-22 繰り返されました Maxim Group Buy
2020-09-01 開始されました BTIG Research Buy
2020-07-15 繰り返されました H.C. Wainwright Buy
すべてを表示

Inmune Bio Inc (INMB) 最新ニュース

pulisher
01:30 AM

INmune Bio, Inc. (NASDAQ:INMB) Receives $22.80 Average Price Target from Brokerages - Defense World

01:30 AM
pulisher
Apr 06, 2025

Trend Tracker for (INMB) - news.stocktradersdaily.com

Apr 06, 2025
pulisher
Apr 01, 2025

INmune Bio Presents MINDFuL Trial Data At AD/PD 2025 - Nasdaq

Apr 01, 2025
pulisher
Apr 01, 2025

INmune Bio Presents Baseline Data From MINDFuL Phase II Trial In Early Alzheimer's Disease - Nasdaq

Apr 01, 2025
pulisher
Apr 01, 2025

INmune Bio presents early Alzheimer’s trial data at AD/PD - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study - The Manila Times

Apr 01, 2025
pulisher
Apr 01, 2025

INmune Bio presents early Alzheimer’s trial data at AD/PD By Investing.com - Investing.com UK

Apr 01, 2025
pulisher
Apr 01, 2025

Promising Patient Profile Emerges in Major Alzheimer's Drug Trial: 69% Carry Key Risk Gene - Stock Titan

Apr 01, 2025
pulisher
Mar 31, 2025

Raymond James maintains INmune Bio stock with $23 target By Investing.com - Investing.com Australia

Mar 31, 2025
pulisher
Mar 31, 2025

Raymond James maintains INmune Bio stock with $23 target - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

Raymond James Financial Inc. Takes Position in INmune Bio, Inc. (NASDAQ:INMB) - Defense World

Mar 31, 2025
pulisher
Mar 30, 2025

INmune Bio anticipates Alzheimer's trial results within 100 days while advancing therapeutic platforms - MSN

Mar 30, 2025
pulisher
Mar 29, 2025

INmune Bio, Inc. (NASDAQ:INMB) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 29, 2025
pulisher
Mar 28, 2025

Scotiabank Remains a Buy on Inmune Bio (INMB) - The Globe and Mail

Mar 28, 2025
pulisher
Mar 28, 2025

INmune Bio (INMB) Eyes Landmark Developments in 2024 Amid Rising Financial Commitments - GuruFocus

Mar 28, 2025
pulisher
Mar 28, 2025

Earnings call transcript: INmune Bio’s Q4 2024 results highlight innovation focus - Investing.com Australia

Mar 28, 2025
pulisher
Mar 28, 2025

INmune Bio Inc (INMB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance

Mar 28, 2025
pulisher
Mar 28, 2025

INmune Bio Inc (INMB) Q4 2024 Earnings Call Highlights: Strategi - GuruFocus

Mar 28, 2025
pulisher
Mar 28, 2025

INmune Bio Reports 2024 Financial Results and Clinical Progress - TipRanks

Mar 28, 2025
pulisher
Mar 27, 2025

Earnings call transcript: INmune Bio’s Q4 2024 results highlight innovation focus By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

INmune Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025
pulisher
Mar 27, 2025

INmune Bio Inc Reports Q4 EPS of -$0.53 and Revenue of $0.01 Mil - GuruFocus.com

Mar 27, 2025
pulisher
Mar 27, 2025

INMUNE BIO Earnings Results: $INMB Reports Quarterly Earnings - Nasdaq

Mar 27, 2025
pulisher
Mar 27, 2025

INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update - TradingView

Mar 27, 2025
pulisher
Mar 27, 2025

INmune Bio's Triple Threat: Alzheimer's Trial Fully Enrolled, FDA Designations Secured - Stock Titan

Mar 27, 2025
pulisher
Mar 27, 2025

(INMB) On The My Stocks Page - news.stocktradersdaily.com

Mar 27, 2025
pulisher
Mar 26, 2025

What to Expect from INmune Bio's Earnings - Benzinga

Mar 26, 2025
pulisher
Mar 24, 2025

INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025 - The Manila Times

Mar 24, 2025
pulisher
Mar 24, 2025

INmune Bio Sets Key Q4 Earnings Date: Critical Updates Expected for Clinical Pipeline - Stock Titan

Mar 24, 2025
pulisher
Mar 21, 2025

Undercovered Dozen: INmune Bio, Primerica, First Quantum, Pinnacle West + - Seeking Alpha

Mar 21, 2025
pulisher
Mar 20, 2025

INmune Bio (INMB) Projected to Post Quarterly Earnings on Thursday - Defense World

Mar 20, 2025
pulisher
Mar 18, 2025

INmune Bio: CORDStrom Is A Game-Changer, As Investors Await Alzheimer's Results (INMB) - Seeking Alpha

Mar 18, 2025
pulisher
Mar 13, 2025

Analysts Set INmune Bio, Inc. (NASDAQ:INMB) Target Price at $22.80 - Defense World

Mar 13, 2025
pulisher
Mar 11, 2025

INmune Bio, Inc. (NASDAQ:INMB) Position Lifted by Rhumbline Advisers - Defense World

Mar 11, 2025
pulisher
Mar 09, 2025

Protalix BioTherapeutics (NYSE:PLX) and INmune Bio (NASDAQ:INMB) Head-To-Head Review - The AM Reporter

Mar 09, 2025
pulisher
Mar 06, 2025

(INMB) Investment Analysis - Stock Traders Daily

Mar 06, 2025
pulisher
Mar 04, 2025

INmune Bio Reports Promising Phase I/II Trial Results - TipRanks

Mar 04, 2025
pulisher
Mar 03, 2025

PMGC Holdings Ends License Agreement with INmune Bio By Investing.com - Investing.com South Africa

Mar 03, 2025
pulisher
Mar 03, 2025

PMGC Holdings Ends License Agreement with INmune Bio - Investing.com

Mar 03, 2025
pulisher
Mar 03, 2025

Why INmune Bio, Inc. (INMB) is Skyrocketing So Far in 2025 - MSN

Mar 03, 2025
pulisher
Mar 01, 2025

Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey

Mar 01, 2025
pulisher
Feb 27, 2025

Is INmune Bio (NASDAQ:INMB) A Risky Investment? - Simply Wall St

Feb 27, 2025
pulisher
Feb 24, 2025

INmune Delivers Impressive 100% Gain In Just 3 MonthsIs There More Room To Run? - RTTNews

Feb 24, 2025
pulisher
Feb 23, 2025

Learn to Evaluate (INMB) using the Charts - Stock Traders Daily

Feb 23, 2025
pulisher
Feb 21, 2025

INmune Bio, Inc. to Host Earnings Call - ACCESS Newswire

Feb 21, 2025
pulisher
Feb 20, 2025

INmune Bio, Inc. (NASDAQ:INMB) most popular amongst individual investors who own 36% of the shares, institutions hold 28% - Yahoo Finance

Feb 20, 2025
pulisher
Feb 20, 2025

INmune Bio, Inc. (NASDAQ:INMB) Receives Consensus Rating of “Buy” from Brokerages - Armenian Reporter

Feb 20, 2025
pulisher
Feb 20, 2025

INmune Bio, Inc. (NASDAQ:INMB) Short Interest Update - MarketBeat

Feb 20, 2025

Inmune Bio Inc (INMB) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$60.29
price down icon 0.48%
$68.09
price down icon 1.58%
$17.32
price down icon 0.23%
$31.03
price down icon 0.26%
$86.82
price down icon 1.40%
biotechnology ONC
$220.54
price down icon 7.53%
大文字化:     |  ボリューム (24 時間):